anti ca19 9 monoclonal antibody 5b1

Drug Overview

The medication known as anti ca19 9 monoclonal antibody 5b1(also identified as LOP628) is an investigational, high-precision oncology agent designed to treat aggressive solid tumors and blood cancers. It is an Antibody-Drug Conjugate (ADC), a class of “smart drugs” that act like a molecular guided missile.

Developed by Novartis, LOP628 is engineered to target the c-Kit receptor (also known as CD117 or SCFR), a protein that is overexpressed or mutated in several types of cancer. By locking onto this specific receptor, LOP628 delivers a lethal chemotherapy payload directly inside the tumor cell, significantly reducing the “collateral damage” typically associated with traditional, non-targeted chemotherapy.

• Generic Name: Anti-c-Kit antibody-drug conjugate LOP628.
• Drug Class: Antibody-Drug Conjugate (ADC) / Microtubule Inhibitor.
• Target: c-Kit (CD117 / Stem Cell Factor Receptor).
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational/Discontinued. As of 2026, LOP628 is no longer in active clinical development. While it completed Phase I trials, the drug was discontinued due to severe safety concerns discovered during its initial testing.

What Is It and How Does It Work? (Mechanism of Action)

LOP628 functions through a sophisticated “Trojan Horse” mechanism. It consists of three parts: a humanized antibody that targets c-Kit, a stable chemical linker, and a powerful cytotoxic payload called DM1 (a maytansinoid derivative).

The c-Kit Target

The c-Kit receptor is a protein found on the surface of several types of cancer cells, including Gastrointestinal Stromal Tumors (GIST), Mast Cell Leukemia, and Small Cell Lung Cancer. In healthy cells, c-Kit is important for the development of blood cells, melanocytes, and germ cells.

Molecular Level Mechanisms

1. Selective Binding: After being infused into the blood, LOP628 circulates until it encounters a cell displaying the c-Kit receptor. It binds to the receptor with high affinity.
2. Internalization: Once bound, the cancer cell “swallows” the entire ADC-receptor complex through a process called endocytosis.
3. Payload Release: Inside the cell’s lysosomes, enzymes break down the linker, releasing the active drug, DM1, into the cell’s interior (cytoplasm).
4. Microtubule Disruption: DM1 is a potent microtubule inhibitor. It binds to tubulin and prevents the cell from building the internal “skeleton” it needs to divide. This causes the cancer cell to freeze during division, leading to cell cycle arrest and eventually apoptosis (programmed cell death).
5. Mast Cell Activation: A unique and unintended effect of LOP628 was its ability to trigger mast cells (a type of immune cell) to release large amounts of histamine, even if they weren’t cancerous.

FDA Approved Clinical Indications

There are currently no FDA-approved indications for LOP628.

During its clinical life, it was investigated in a Phase I trial (NCT01922115) for:

• Gastrointestinal Stromal Tumors (GIST): For patients who were resistant to standard treatments like Imatinib.
• Mast Cell Leukemia/Systemic Mastocytosis: Targeting the abnormal c-Kit signaling that drives these rare blood cancers.
• Other c-Kit Positive Solid Tumors: Including specific types of lung and skin cancers.

Dosage and Administration Protocols

Because the drug was discontinued during Phase I, there is no established “standard” dose. The following information is based on the protocols used during its initial dose-escalation research.

Clinical Efficacy and Research Results

The clinical journey of LOP628 was cut short, providing a critical cautionary tale for ADC development.

• Rapid Discontinuation: The Phase I trial was stopped prematurely after only 12 patients were treated.
• Safety Failure: Despite promising preclinical data, the drug caused severe, immediate allergic-like reactions in the first few patients, even at very low doses.
• Mechanism of Failure: Research revealed that the way LOP628 bound to c-Kit actually caused mast cell degranulation. Essentially, the drug was “accidentally” triggering a massive release of histamine and other chemicals from healthy immune cells, making it too dangerous for human use in its original form.

Safety Profile and Side Effects

The primary reason for the failure of LOP628 was the occurrence of infusion-related hypersensitivity reactions, which were severe and unexpected.

Common Side Effects:

• Fatigue: A general sense of tiredness.
• Nausea/Vomiting: Common with the DM1 payload.
• Skin Rash/Itching.

Serious Adverse Events (The “Deal-Breakers”):

• Hypersensitivity/Anaphylaxis: Patients experienced rapid onset of hives, difficulty breathing, and drops in blood pressure immediately after starting the IV infusion.
• Mast Cell Degranulation: Massive release of inflammatory chemicals into the bloodstream.
• Hepatotoxicity: Some elevation of liver enzymes was noted in the early doses.
• Management Strategy: While the trial team attempted to use “pre-medications” like steroids and antihistamines, these were not sufficient to prevent the severe reactions, leading to the drug’s permanent discontinuation.

Research Areas

In the field of Stem Cell and Regenerative Medicine, c-Kit (CD117) is one of the most important markers for Hematopoietic Stem Cells (HSCs)—the cells that make all our blood. Researchers used the data from LOP628 to better understand how to target cancer without damaging the healthy stem cell “niche.” The failure of LOP628 has led to the development of “next-generation” c-Kit antibodies that are designed specifically not to activate mast cells, potentially allowing for safer bone marrow transplants in the future.

Patient Management and Practical Recommendations

Pre-treatment Tests (Historically Required):

• c-Kit Expression Screening: A biopsy to confirm the tumor has the receptor.
• Baseline Mast Cell Count: To assess the risk of a severe allergic reaction.
• Liver and Kidney Function Tests: Essential for safe drug processing.

Precautions:

• Immediate Monitoring: Patients on c-Kit targeted therapies must be monitored by a medical team equipped to handle anaphylaxis (severe allergic reaction).
• Allergy Awareness: Report any history of severe allergies or “Mast Cell Activation Syndrome” to your oncologist.

“Do’s and Don’ts” List:

• DO report any “flushing,” itching, or chest tightness immediately during an infusion.
• DO stay in the clinic for the required observation period after your dose.
• DON’T skip pre-medications (like Benadryl or steroids) if they are prescribed by your oncology team.
• DON’T ignore minor rashes, as these can be early warning signs of a larger reaction.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. LOP628 is an investigational agent that has been discontinued from clinical development. It is not approved by the US Food and Drug Administration (FDA) for any indication. Always consult with a qualified oncologist regarding currently available and approved treatments for your specific condition.